Public Company Appoints Smith Anderson Attorney Santo J. Costa as Chairman of the Board of Directors
Aquestive Therapeutics, a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs, has announced that its Board of Directors has appointed Smith Anderson attorney Sandy Costa as Chairman, effective August 8th.
Sandy joined Aquestive's Board in 2015 bringing over 40 years of experience in the pharmaceutical, health care and life sciences industries as well as leadership in the legal sector. He is also a nationally recognized speaker on leadership, former President of Quintiles Transnational and author of the book “Humanity at Work: Encouraging Spirit, Achievement and Truth to Flourish in the Workplace.” In addition to Aquestive, Sandy currently sits on the boards of Cytokinetics Inc., Metabolon Inc. and the North Carolina Biotechnology Center.
In a recent press release from Aquestive, Sandy shared, “Aquestive is uniquely positioned with a broad pipeline that spans late stage CNS candidates and earlier stage orally administrated complex molecules. I look forward to continuing to work with the Board and the executive team as Aquestive transitions to a commercial organization in the coming months.”
Sandy has served as a board member to over 20 public and private companies and charitable organizations. Aside from his legal practice at Smith Anderson, Sandy’s professional experience includes president, chief operating officer, and vice chairman of Quintiles Transnational Corp. where, during his tenure, he had responsibility for all operating divisions and worldwide business development. Other corporate experience includes executive level roles at Glaxo Inc.
About Aquestive Therapeutics
Aquestive Therapeutics is a specialty pharmaceutical company focused on identifying, developing and commercializing differentiated products to address unmet medical needs. Aquestive Therapeutics has a late-stage proprietary product pipeline focused on the treatment of CNS diseases, and is working to advance orally-administered complex molecules that it believes can be alternatives to invasively-administered standard of care therapies. As the leader in developing and delivering drugs via its PharmFilm® technology, Aquestive Therapeutics also collaborates with pharmaceutical partners to bring new molecules to market in differentiated and highly-marketable dosage forms.